BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc.
- Market cap
- $421.97M
Your view on BLSM
Overview
What the company does, where it operates, and who runs it.
About BlossomHill Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jing Rong Jean Cui
- Headquarters
- 10255 Science Center Drive, Suite 200, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jing Rong Jean Cui
- Headquarters
- 10255 Science Center Drive, Suite 200, San Diego, CA, US
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for BlossomHill Therapeutics, Inc.. Starting points for BlossomHill Therapeutics, Inc.: EPS -$2.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for BlossomHill Therapeutics, Inc.. Trailing twelve-month EPS for BlossomHill Therapeutics, Inc. stands at -$2.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
2 ratings- Strong Buy0
- Buy2
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.96 | −$0.88 | −$5.80 | −$3.38 |
| Lowest estimate | −$1.04 | −$0.93 | −$6.33 | −$3.77 |
| Highest estimate | −$0.87 | −$0.82 | −$5.27 | −$2.99 |
| Number of analysts | 2 | 1 | 2 | 3 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | — | — | — | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for BlossomHill Therapeutics, Inc.. BlossomHill Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACTUActuate Therapeutics Inc | Healthcare | Biotechnology | $5.4M | ||
| AGIOAgios Pharmaceuticals, Inc. | Healthcare | Biotechnology | $1.7B | ||
| ALLRAllarity Therapeutics, Inc. | Healthcare | Biotechnology | $12.6M | ||
| AVBPArriVent BioPharma, Inc. Common Stock | Healthcare | Biotechnology | $544.1M | ||
| FHTXFoghorn Therapeutics Inc. | Healthcare | Biotechnology | $103.1M | ||
| FTHFaeth Therapeutics, Inc. | Healthcare | Biotechnology | $203.1M | ||
| GLUEMonte Rosa Therapeutics, Inc. | Healthcare | Biotechnology | $738.3M | ||
| NRIXNurix Therapeutics, Inc. | Healthcare | Biotechnology | $1.4B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $25.1M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $8.2M | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | ASX | — | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.6M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| PYC.AXPYC Therapeutics Limited | Healthcare | ASX | — | ||
| OBXObsidian Therapeutics Inc. | Healthcare | NASDAQ | $12.5M | ||
| OCC.AXOrthocell Limited | Healthcare | ASX | — | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.00% | |
| VTWOVanguard Russell 2000 ETF | $16.6B in assets | 0.00% | |
| VUN.TOVanguard U.S. Total Market Index ETF | $20.1B in assets | 0.00% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.00% | |
| VEQT.TOVanguard All-Equity ETF Portfolio | $17.6B in assets | 0.00% | |
| VGRO.TOVanguard Growth ETF Portfolio | $10.9B in assets | 0.00% | |
| VTWVVanguard Russell 2000 Value ETF | $1.3B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in BLSM.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by BlossomHill Therapeutics, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for BlossomHill Therapeutics, Inc.. Coverage tracks BlossomHill Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of BlossomHill Therapeutics, Inc.